- Record: found
- Abstract: found
- Article: not found
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw
1 ,
Beow Y Yeap ,
Mari Mino-Kenudson ,
Subba R Digumarthy ,
Daniel B Costa ,
Rebecca S Heist ,
Benjamin Solomon ,
Hannah Stubbs ,
Sonal Admane ,
Ultan McDermott ,
Jeffrey Settleman ,
Susumu Kobayashi ,
Eugene J Mark ,
Scott J Rodig ,
Lucian R Chirieac ,
Eunice L Kwak ,
Thomas J Lynch ,
A John Iafrate
Sep 10 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The EML4-ALK fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLC). To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK.